key: cord-0701855-65bp6vcp
authors: S K, Shini Rubina; P A, Anuba; B, Swetha; kalala, Kavya Priya; PM, Aishwarya; Sabarathinam, Sarvesh
title: Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases
date: 2022-03-07
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2022.102451
sha: fc68dcc6c85c29643181ff636755d847133ff464
doc_id: 701855
cord_uid: 65bp6vcp

BACKGROUND AND AIMS: This Review discusses the potential drug interactions risk between Drugs used in treating COVID-19 infection and Drugs used in treating comorbid conditions (Diabetes, hypertension, cardiovascular illness). METHOD: Six Databases were consulted a) Micromedex drug interaction b) Medicine complete.com c) Liverpool Drug Interaction Group for COVID-19 therapies d) Epocrates e) Medscape f) drugs.com. To acquire information on possible interaction effects between drugs used for COVID-19 treatment such as atazanavir, lopinavir/ritonavir, remdesivir, molnupiravir, paxlovid(nirmatrelvir/ritonavir), dexamethasone, azithromycin, chloroquine, and FDA approved monoclonal antibodies with primarily used antidiabetic drugs, antihypertensive drugs, and drugs acting on the cardiovascular system. RESULTS: Potential interaction effects such as worsening glycemic control were prominent with lopinavir/ritonavir and the primarily used antidiabetic drugs, which needs dosage adjustment and close monitoring. The risk of hypotension and irregular heart rhythm is the potential interaction effects with concomitant use of drugs for COVID-19 treatment and antihypertensive drugs. Caution is advised with drugs such as atazanavir and lopinavir/ritonavir when concomitantly used in treating comorbid conditions. Drugs such as remdesivir, molnupiravir, and some monoclonal antibodies are safer in use with drugs used in treating the comorbid condition. CONCLUSIONS: Drug-drug interaction remains one of the significant factors in altering the therapeutic efficacy. Drugs used to manage comorbid conditions may influence the COVID-19 treatment with potential interaction effects. These enhance the view on safety concerns about the drug interaction risk in managing COVID-19 infection in patients with comorbid conditions. This primary evidence may concern preventing potential or unintentional effects resulting from Drug-drug interaction, Improving patient quality of life.

Under FDA-issued emergency use authorization, antiviral pharmaceuticals (e.g., immunomodulatory therapy are accessible as an option for pharmacological management. 7,8 63 Treatment of complex diseases frequently necessitates the use of multiple drugs 64 simultaneously. Polypharmacy raises the risk of drug-drug interaction and reduces patient compliance. Drug combination therapy can be very effective, but it is also associated with drug-66 drug interactions. COVID-19 Patients with underlying diseases are more likely to have drug 67 interactions as they frequently require multiple medications. Drug interactions may put the 68 patient at risk of severe adverse effects and reduce treatment safety and efficacy. Therefore, 69 there must be a significant concern in managing their conditions. This Review discusses the 70 potential interaction effects between the drugs used in COVID-19 treatment and drugs 71 primarily used for cardiovascular and comorbid conditions such as diabetes and hypertension. approved antiviral drugs such as molnupiravir, paxlovid(nirmatrelvir/ritonavir), which gives 83 concern to the new strains of SARS-Cov-2. Molnupiravir is a prodrug of N-hydroxycytidine 84 (NHC) with activity against SARS-CoV-2 and other RNA viruses and a high barrier to 85 resistance development. 10 Molnupiravir found to follow "error catastrophe" mechanism, which 86 is built on the concept that increasing the rate of mutation in the viral genome beyond a 87 biologically tolerable threshold will render the virus lethal and lead to its extinction. 11 Paxlovid 88 is a brand name for a combination therapy that includes nirmatrelvir and ritonavir. Nirmatrelvir preventing the viral RNA genome from being released into the cytosol. 14 The cytokine storms 107 activated by the overproduction of proinflammatory cytokines were observed in COVID-19 108 patients. In such conditions, proinflammatory cytokines such as interleukin 1 (IL-1) and 109 interleukin 6 (IL-6) levels are typically elevated. Drugs that inhibit the biological activity of 110 IL-1 and its downstream product, IL-6, may help treat SARS-CoV-2 infection. 15 Currently, the 111 COVID-19 treatment guidelines have recommended using two drugs such as Sarilumab and moderately interact with some antihypertensive drugs that need monitoring of parameters, as explained in Table 3 . As drug interaction potentially results in toxicity effects or therapeutic 157 failure, concern on the coadministration of drugs is mandatory. These interactions may or may 158 not affect therapy based on the individual patient's pharmacokinetics and pharmacodynamics.

Therefore, There is a need for health care professionals to be aware of potential effects 160 associated with drug interactions. Table 3 . Hypotension, irregular heart rhythm, electrocardiographic (ECG) changes are the 234 potential effects of drug interaction with COVID-19 treatment drugs and antihypertensive 235 drugs. Interaction with major severity is found between atazanavir and beta-blockers 236 (propranolol, atenolol), resulting in irregular heart rhythm or additive PR interval prolongation.

Concurrent use is not recommended, In case of necessity, their ECG parameters are to be 238 monitored during treatment. More than three databases conveyed Possible interactions with 239 Amlodipine and atazanavir. Its effect remains with major severity, increasing risk of 240 cardiotoxicity PR interval prolongation are considered to be the effects of major severity.

Therefore, Routine ECG monitoring is required. The same interaction effect is also seen with 242 remains mandatory during their treatment, this review highlights the possible effects of drug 

New insights on the antiviral effects of 339 chloroquine against coronavirus: what to expect for COVID-19?

Role of monoclonal antibody drugs in the treatment 342 of COVID-19